UK medicines regulator approves gene therapy for two blood disorders
by Denis Campbell Health policy editor from Science | The Guardian on (#6GDRD)
MHRA authorises uses of Casgevy as a potential cure for sickle cell disease and beta thalassemia
Britain's drugs regulator has approved a groundbreaking treatment for two painful and debilitating lifelong blood disorders, which works by editing" the gene that causes them.
The Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light for Casgevy to be used to treat sickle cell disease and beta thalassemia.
Continue reading...